Erythromycin Ophthalmic Ointment USP, 0.5% (Sterile)

Manufacturer
Rebel Distributors Corp
Effective date
2010-09-27
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:10:28

Label at a glance#

ProductErythromycin
Active ingredientERYTHROMYCIN
Label structure11 sections

Indications and uses

For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis . The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrhoeae is not established. For infants born to mothers with clinically apparent gonorr...

Dosage and administration

In the treatment of superficial ocular infections, erythromycin ophthalmic ointment approximately 1 cm in length should be applied directly to the infected eye(s) up to six times daily, depending on the severity of the infection. For prophylaxis of neonatal gonococcal or chlamydial ophthalmia, a ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. The ointment shoul...

Storage and handling

Store between 15°-30°C (59°-86°F). KEEP OUT OF REACH OF CHILDREN. Revised February 2007 Rx only

Label contents#

Full prescribing information#

Description

DESCRIPTION SECTION

Erythromycin Ophthalmic Ointment USP belongs to the macrolide group of antibiotics. The sterile ophthalmic ointment flows freely over the conjunctiva. Erythromycin base, as crystals or powder, is slightly soluble in water, moderately soluble in ether, and readily soluble in alcohol or chloroform. Erythromycin is an antibiotic produced from a strain of Streptomyces erythraeus. It is basic and readily forms a salt when combined with an acid. It has the following structural formula:

Chemical Structure
Chemical Structure

C37H67NO13

Mol. Wt. 733.94

Chemical Name: (3R•, 4S•, 5S•, 6R•, 7R•, 9R•, 11R•, 12R•, 13S•, 14R•)-4-[(2,6-Dideoxy-3-C-methyl-3-0-methyl-α-L-ribo-hexopyranosyl)oxy]-14-ethyl-7, 12, 13-trihydroxy-3, 5, 7, 9, 11, 13 hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-opyranosyl]oxy]oxacyclotetradecane-2, 10-dione

Each Gram Contains: ACTIVE: Erythromycin, USP 5 mg (0.5%); INACTIVES: White Petrolatum, Mineral Oil.

Clinical Pharmacology

CLINICAL PHARMACOLOGY SECTION

Microbiology

SPL UNCLASSIFIED SECTION

Erythromycin inhibits protein synthesis without affecting nucleic acid synthesis. Erythromycin is usually active against the following organisms in vitro and in clinical infections: Streptococcus pyogenes (group A β-hemolytic), Alpha-hemolytic streptococci (viridans group); Staphylococcus aureus, including penicillinase-producing strains (methicillin-resistant staphylococci are uniformly resistant to erythromycin); Streptococcus pneumoniae; Mycoplasma pneumoniae (Eaton Agent, PPLO); Haemophilus influenzae (not all strains of this organism are susceptible at the erythromycin concentrations ordinarily achieved); Treponema pallidum; Corynebacterium diphtheriae; Neisseria gonorrhoeae; Chlamydia trachomatis.

Indications and Usage

INDICATIONS & USAGE SECTION

For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin.

For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis.

The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrhoeae is not established.

For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants.

Contraindications

CONTRAINDICATIONS SECTION

This drug is contraindicated in patients with a history of hypersensitivity to erythromycin.

Precautions

SPL UNCLASSIFIED SECTION

General

GENERAL PRECAUTIONS SECTION

The use of antimicrobial agents may be associated with the overgrowth of non-susceptible organisms including fungi; in such a case, antibiotic administration should be stopped and appropriate measures taken.

Information for patients

INFORMATION FOR PATIENTS SECTION

Avoid contaminating the tip of container with material from the eye, fingers or other source.

Carcinogenesis, mutagenesis, impairment of fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Avoid contaminating the tip of container with material from the eye, fingers or other source.

Pregnancy

SPL UNCLASSIFIED SECTION

Pregnancy Category B

SPL UNCLASSIFIED SECTION

Reproduction studies have been performed in rats, mice, and rabbits using erythromycin and its various salts and esters, at doses that were several multiples of the usual human dose. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, the erythromycins should be used during pregnancy only if clearly needed.

Nursing mothers

NURSING MOTHERS SECTION

Caution should be exercised when erythromycin is administered to a nursing woman.

Adverse Reactions

ADVERSE REACTIONS SECTION

The most frequently reported adverse reactions are minor ocular irritations, redness and hypersensitivity reactions.

Dosage and Administration

DOSAGE & ADMINISTRATION SECTION

In the treatment of superficial ocular infections, erythromycin ophthalmic ointment approximately 1 cm in length should be applied directly to the infected eye(s) up to six times daily, depending on the severity of the infection.

For prophylaxis of neonatal gonococcal or chlamydial ophthalmia, a ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. The ointment should not be flushed from the eye following instillation. A new tube should be used for each infant.

How Supplied

HOW SUPPLIED SECTION

Erythromycin Ophthalmic Ointment USP, 0.5% is available in the following sizes:

1/8 oz. (3.5 g) tamper-resistant tube – 09234

DO NOT USE IF CAP AND NECKRING ARE NOT INTACT.

DO NOT USE IF BOTTOM RIDGE OF TUBE CAP IS EXPOSED.

Storage

STORAGE AND HANDLING SECTION

Store between 15°-30°C (59°-86°F).

KEEP OUT OF REACH OF CHILDREN.

Revised February 2007

Rx only

Manufacturer Information

SPL UNCLASSIFIED SECTION

Bausch & Lomb Incorporated
Tampa, FL 33637
©Bausch & Lomb Incorporated

Repackaged by:

Rebel Distributors Corp

Thousand Oaks, CA 91320

Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Erythromycin OphthalmicErythromycin Ophthalmic

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
310149erythromycin 0.5 % (5 MG/GM) Ophthalmic OintmentPSN1
310149erythromycin 0.005 MG/MG Ophthalmic OintmentSCD1
310149erythromycin 0.5 % Ophthalmic OintmentSY1
310149erythromycin 5 MG per GM Ophthalmic OintmentSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
ERYTHROMYCIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
d329c2e1-5ae8-4e64-aea0-77ecea3fa1abProduct name320250717
3b331500-3b74-bd2b-fede-d46839f2f4d5Product name620240313
fdae2630-eae0-4769-abfd-8f33d5b771b4Product name320240202
8c898317-b543-1e4e-254f-84cec2f3f57eProduct name220191002
64ae94c0-3212-d73a-92da-9e6dd85c6ebeProduct name220180118
edcfa1cf-915f-1a4c-d0aa-508cc66e70d9Product name220170816
ad75fcfd-a339-42a1-9c60-43ba2c654cfaProduct name120170810
57850177-5927-151f-e1fa-7e2ca47f81e5Product name120140508
8ee71591-1d8f-e24e-242b-bfef131e3168Product name120140508
bff5cf99-0f45-fa15-2a76-b160c3c4cc3cProduct name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
21695-173-352019-09-24C16284748780-1934fe258-47c7-48b1-e053-8cdaa90a720aErythromycin Ophthalmic Ointment USP, 0.5% (Sterile)

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
21695-173-35Erythromycin1 in 1 CARTONOINTMENT11
21695-173-35Erythromycin3.5 g in 1 TUBEOINTMENT3.51

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
21695-173ERYTHROMYCIN OINTMENT [REBEL DISTRIBUTORS CORP]1Legacy NDC, 2 package rows20101119_d8b0abac-c32c-4bd0-8247-5c6d6a9fd17f.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
24208-910-19GM - Gram24208-9108e929d63-aea2-4e45-9ec1-4a255e8b769b12012-07-24
24208-910-55GM - Gram24208-9106a54f741-6969-4285-b0d6-73acf01c98dc12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
ERYTHROMYCINACTIVE INGREDIENT63937KV33D1
ERYTHROMYCINACTIVE MOIETY63937KV33D1
MINERAL OILINACTIVE INGREDIENTT5L8T28FGP1
PETROLATUMINACTIVE INGREDIENT4T6H12BN9U1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 3 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
21695-17321695-173-35
24208-910

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 3 matching rows.

Name, UNII, Kind table
NameUNIIKind
ERYTHROMYCIN63937KV33DACTIB
PETROLATUM4T6H12BN9UIACT
MINERAL OILT5L8T28FGPIACT

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 2 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
MINERAL OILMINERAL OILT5L8T28FGPOINTMENT / OPHTHALMIC59.5 %w/wExact identifier — unii+route+dosage form
PETROLATUMPETROLATUM4T6H12BN9UOINTMENT / OPHTHALMIC88.4 %w/wExact identifier — unii+route+dosage form

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A064067-001ERYTHROMYCINERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-29

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A064067-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-2984e616aacf4f…
2026-08-18 06:07:402026-07A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-29caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-29011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-2931067a03dcf5…
2025-08-23 18:47 UTC2025-08A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-296a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-29fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-29b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-2903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-292680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-295bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-29d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-29d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-2979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-29301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-291e350fbaab3a…
2024-05-31 18:47 UTC2024-05A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-298072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-295c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-295d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-294b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-2974a2ff9319b5…
2022-03-09 01:35 UTC2022-03A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-29bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-29782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-2987673890dc5c…
2021-03-12 10:30 UTC2021-03A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-295aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-298869cabd3fbd…
2020-11-12 02:37 UTC2020-11A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-29c0c555d07b60…
2019-12-14 00:12 UTC2019-12A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-293f01610625f2…
2019-09-15 20:21 UTC2019-09A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-29b00525d2431f…
2019-07-19 19:46 UTC2019-07A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-29ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-296a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-291c564ffb4f44…
2023-12-20 04:57 UTC2023-12A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-29ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-29a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-299b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-29a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-293f0d92c62455…
2023-05-13 08:27 UTC2023-05A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-29053a50430f4f…
2023-01-26 05:58 UTC2023-01A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-293bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-293a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-29f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A064067-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A064067-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A064067-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A064067-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A064067-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A064067-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A064067-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A064067-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A064067-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A064067-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A064067-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A064067-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A064067-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A064067-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A064067-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A064067-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A064067-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A064067-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A064067-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A064067-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A064067-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A064067-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A064067-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A064067-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A064067-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A064067-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A064067-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A064067-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A064067-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A064067-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A064067-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A064067-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A064067-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A064067-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A064067-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A064067-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A064067-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A064067-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A064067-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A064067-001AT1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ErythromycinERYTHROMYCINBausch & Lomb Incorporated061ddd20-94a6-4e3c-ba84-1ebd8529eea62026-08-28Adverse reactionsExact identifier
ndc (product): 24208-910
d8b0abac-c32c-4bd0-8247-5c6d6a9fd17fd8b0abac-c32c-4bd0-8247-5c6d6a9fd17f2010-09-27Adverse reactionsExact identifier
spl id: d8b0abac-c32c-4bd0-8247-5c6d6a9fd17f
spl set id: d8b0abac-c32c-4bd0-8247-5c6d6a9fd17f

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.